Reference

MSAN(2021)34

Name

Tocilizumab (RoActemra®) 162mg/0.9ml solution for injection pre-filled syringes and pre-filled pens – Non Covid-19 indications

Categories

Scottish Government

Organization

Scottish Government Health and Social Care Directorates

Keywords

NHS SCOTLAND DRUGS PHARMACEUTICAL INDUSTRY DRUG THERAPY PHARMACEUTICAL SERVICES SUPPLIES

Description

1. Tocilizumab (RoActemra®) 162mg/0.9ml solution for injection pre-filled syringes and pre-filled pens are in limited supply until January 2022 due to increased global demand on the active pharmaceutical ingredient. 2. Prescribers should urgently review their Rheumatoid Arthritis guidelines and amend in line with the advice in the clinical prioritisation section of this Medicine Supply Alert Notice (MSAN) 3. Remaining stock should be prioritised for patients already established on these formulations and new patients, as outlined in the clinical prioritisation advice below. 4. Tocilizumab (RoActemra®) solution for infusion vials, which are also used in Covid-19 patients, are not covered by this MSAN but supply remains constrained. 5. Sarilumab (Kevzara®) solution for injection pre-filled pens should be considered the first line agent for treatment of Rheumatoid Arthritis when an IL-6 antagonist is indicated and can support an increase in demand. Sarilumab (Kevzara®) solution for injection pre-filled syringes are unable to support an uplift in demand. 6. Sarilumab (Kevzara®) nurse injection training and initiation at patient's home is not funded by Sanofi and the initiatingBoard will need to ensure that appropriate training is available, either on site or in patient’s homes.

Contact Name

Contact Email

Contact Address

Contact Phone

Created

2021-11-09 00:00:00

Download URL